Table of Content


1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Approval of New HPV Vaccines
4.2.2 Increasing initiatives by Government & Private Organizations for Early Screening & Vaccination
4.3 Market Restraints
4.3.1 Stringent Regulation
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Bivalent
5.1.2 Quadrivalent
5.1.3 Nonavalent
5.2 By Indication
5.2.1 Cervical Cancer
5.2.2 Anal Cancer
5.2.3 Penile Cancer
5.2.4 Oropharyngeal Cancer
5.2.5 Genital Warts
5.2.6 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co., Inc.,
6.1.2 GlaxoSmithKline Plc
6.1.3 Sanofi S.A.
6.1.4 Johnson & Johnson
6.1.5 AstraZeneca Plc
6.1.6 Serum Institute of India Pvt. Ltd.
6.1.7 Bharat Biotech


7 MARKET OPPORTUNITIES AND FUTURE TRENDS